ArticleRadiation oncology journal2022
Journey to hypofractionation in radiotherapy for breast cancer: critical reviews for recent updates.
Article in Radiation oncology journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07344597 (Prospective Comparative Study of Hypofractionated Adjuvant Radiotherapy in 2 Virsus 3 Weeks in Breast Cancer), which is not on this map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Prospective Comparative Study of Hypofractionated Adjuvant Radiotherapy in 2 Virsus 3 Weeks in Breast Cancer
Who cites it
11 citing papers in PubMed, 23 citations in OpenAlex.
- A novel, multi-active emollient for the prevention of acute radiation dermatitis in breast cancer patients: a randomized clinical trial.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2023Trial
- Article
- Optimal Fractionation Scheduling for Radiotherapy Treatments with Reinforcement Learning, Tumor Growth Modeling and Outcome Modeling.Biomedicines · 2025Article
- Smoking increases breast toxicity despite adjuvant hypofractionated IMRT in early breast cancer.Radiation oncology (London, England) · 2025Article
- The Effect of Ionising Radiation on the Properties of Tumour-Derived Exosomes and Their Ability to Modify the Biology of Non-Irradiated Breast Cancer Cells-An In Vitro Study.International journal of molecular sciences · 2025Article
- Understanding the risk of ionizing radiation in breast imaging: Concepts and quantities, clinical importance, and future directions.European journal of radiology · 2024Review
- Clinical indications and future directions of carbon-ion radiotherapy: a narrative review.Ewha medical journal · 2024Review
- Outcomes of whole breast radiation therapy in Asian breast cancer patients with prior cosmetic implants.Breast cancer (Tokyo, Japan) · 2024Article
- An IMRT planning technique for treating whole breast or chest wall with regional lymph nodes on Halcyon and Ethos.Journal of applied clinical medical physics · 2024Article
- Symptomatic Calcifications after Mastectomy: A Rare Case Report with a Review of the Literature.Medicina (Kaunas, Lithuania) · 2024Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Historical conventional fractionated radiation therapy (RT) for breast cancer consisted of 1.8-2.0 Gy per fraction with a total dose of 45-60 Gy over 5-7 weeks. Based on radiobiological characteristics, a low α/β is suspected of breast cancer resulting in sensitivity to higher dose per fraction (2.5-3.0 Gy). Over the past 10 years, multiple clinical trials support the application of shorter treatment regimen with hypofractionated RT (HypoRT). Recently, ultra-HypoRT with 5 fractions showed favorable outcomes. Although the safety and efficacy of HypoRT has been supported by high-quality randomized trials, there are still some worries and doubts around HypoRT from radiation oncologists. However, the radiation oncology community have now reached an important timepoint for adopting HypoRT during the COVID-19 pandemic. The aim of this review is to provide an overview of HypoRT in breast cancer based on prospective randomized trials and discuss the special consideration regarding HypoRT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.